Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.
OBJECTIVE To assess the effect of orlistat on body weight and cardiovascular risk amongst obese patients at high coronary risk . DESIGN After screening , patients entered a two-week single-blind placebo lead-in period , during which they followed a mildly hypocaloric diet , before being r and omized to double-blind treatment with either orlistat 120 mg or placebo three times daily , in conjunction with dietary intervention for 1 years . SETTING The study was conducted at 33 primary care centres in Sweden . SUBJECTS A total of 382 obese adults ( body mass index 28 - 38 kg m-2 ) with type 2 diabetes , hypercholesterolaemia and /or hypertension were recruited , of whom 376 were r and omized to orlistat ( n = 190 ) or placebo ( n = 186 ) . MAIN OUTCOME MEASURES Change in body weight , waist and hip circumferences , blood pressure , serum lipid profile , fasting glucose and HbA1c . RESULTS After 1 years , mean weight loss was significantly greater with orlistat compared with placebo ( 5.9 % vs. 4.6 % ; P < 0.05 ) . Moreover , significantly more orlistat-treated patients than placebo recipients maintained weight loss of > or = 5 % ( 54.2 % vs. 40.9 % ; P < 0.001 ) . Orlistat was also associated with significantly greater improvements than placebo in total serum cholesterol ( - 3.3 % vs. -0.5 % ; P < 0.05 ) , LDL-cholesterol ( - 7.0 % vs. -1.1 % ; P < 0.05 ) , fasting glucose ( 5.1 % vs. -0.1 % ; P < 0.01 ) and HbA1c ( - 2.7 % vs. -0.5 % ; P < 0.05 ) . Similar results were reported for the subgroup of patients with type 2 diabetes . Orlistat was well tolerated . CONCLUSIONS Treatment with orlistat in conjunction with diet promotes significantly greater weight loss and cardiovascular risk factor reduction than diet alone amongst obese patients at high risk of future coronary events
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .